新國都(300130.SZ):擬推2025年股票期權激勵計劃
格隆匯5月27日丨新國都(300130.SZ)公佈2025年股票期權激勵計劃(草案),本計劃授予的股票期權所涉及的標的股票總數爲1,900萬股,佔本激勵計劃草案公告時公司股本總額567,299,123股的3.35%。
每份股票期權擁有在激勵計劃有效期內的可行權日以行權價格購買1股新國都股票的權利。本計劃的股票來源爲新國都向激勵對象定向發行的公司A股普通股股票。
本計劃授予的股票期權的行權價格爲25元/份。
本激勵計劃的有效期爲自股票期權授權之日起至激勵對象獲授的股票期權全部行權或註銷完畢之日止,最長不超過36個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.